Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD Access the segment here ISELIN, N.J., Jan.

Pravin U. Dugel, MD, Ocular's Executive Chairman, President and CEO, will provide an update regarding the enrollment status ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

A recent study found that the triple-layer sign (TLS) obtained on optical coherence tomography has high sensitivity and ...

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

Reticular pseudodrusen and subretinal hyperreflective material are among the OCT findings that may predict macular atrophy in ...

But your vision loss that you think is normal, may be an advanced form of macular degeneration, or loss of vision ... But there is a treatment for the condition called Izervay that shows great promise ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema ...

INR:1974. scrum poker️ The real challenge that DRG poses to private hospitals Two blockbuster generic drugs from Qilu were approved: albumin paclitaxel for injec ...

Investigators conducted a meta-analysis of randomized controlled trials to assess the efficacy and safety of brolucizumab ...